The Klein Law Firm
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCIV, ATHA and REKR
NEW YORK, NY / ACCESSWIRE / July 20, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Churchill Capital Corp IV (NYSE:CCIV)
Class Period: January 11, 2021 - February 22, 2021
Lead Plaintiff Deadline: August 30, 2021
The CCIV lawsuit alleges Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Learn about your recoverable losses in CCIV: http://www.kleinstocklaw.com/pslra-1/churchill-capital-corp-iv-loss-submission-form?id=17818&from=1
Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline: August 24, 2021
During the class period, Athira Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
Learn about your recoverable losses in ATHA: https://www.kleinstocklaw.com/pslra-1/athira-pharma-inc-loss-submission-form?id=17818&from=1
Rekor Systems, Inc. f/k/a Novume Solutions, Inc. (NASDAQ:REKR)
Class Period: April 12, 2019 - May 25, 2021
Lead Plaintiff Deadline: August 30, 2021
The complaint alleges that during the class period Rekor Systems, Inc. f/k/a Novume Solutions, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Rekor's automatic license plate recognition ("ALPR") technology and uninsured vehicle enforcement diversion ("UVED")-related business is outclassed by global competitors with an established, dominant market share; (ii) it was unlikely that states would pass legislation authorizing deals similar to Rekor's Oklahoma UVED partnership because of, inter alia, state and local privacy laws and related public concerns; (iii) Rekor's UVED partnership was not as profitable as Defendants had led investors to believe because of known impediments to enrollment rates and costs associated with the partnership; (iv) accordingly, Rekor had overstated its potential revenues, profitability, and overall ALPR- and UVED-related business prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in REKR: https://www.kleinstocklaw.com/pslra-1/rekor-systems-inc-f-k-a-novume-solutions-inc-loss-submission-form?id=17818&from=1To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
KOMO Plant Based Foods Inc.3.8.2021 12:01:52 CEST | Press release
Komo Plant Based Foods Announces DTC Eligibility
FireFox Gold Corp3.8.2021 11:32:20 CEST | Press release
FireFox Reports Significant Gold from First-Ever Drilling at the Saittavaara Prospect, on the Jeesiö Project in Northern Finland
Achieve Life Sciences, Inc.3.8.2021 11:31:49 CEST | Press release
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
Link Global Technologies Inc.3.8.2021 09:04:49 CEST | Press release
Link Global Technologies Enters into an $18 Million Equity Facility with Alumina Partners, LLC
Sanara MedTech Inc.2.8.2021 15:16:57 CEST | Press release
Sanara MedTech Inc. Announces Second Quarter 2021 Earnings Release and Conference Call Dates
Loop Industries, Inc.2.8.2021 15:03:06 CEST | Press release
Loop Industries and SK global chemical Close $56.5M Strategic Equity Deal, Provide Further Update on Asian Joint Venture to Manufacture 100% Recycled PET Plastic
Kingstone Companies, Inc2.8.2021 15:02:36 CEST | Press release
Kingstone Announces Estimated Prior Quarter Catastrophe Losses Kingstone Declares Quarterly Dividend of $0.04 per share
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom